Follow us on Sample Clauses

Follow us on. This publication has been prepared for general guidanceon matters of interest only, and does not constitute professionaladv ice. You should not act upon the information contained in this publication without obtaining specific professional advice. No representation or warranty (express or implied) is given as to the accuracy or completeness of the information contained in this publication, and, to the extent permitted by law, Lawgical Startup, its members, employees and agents accept no liability, and disclaim all responsibility, forthe consequences of you or anyoneelse acting, or refraining to act, in reliance on the information contained in this publication or for any decision based on it. Without prior permission of Lawgical Startup, this publication may not be quoted in whole or in part or otherwise referred to in any documents.

Follow us on. LinkedIn: Mesoblast Limited Twitter: @Mesoblast This announcement includes forward-looking statements that relate to future events or Mesoblast’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Mesoblast’s actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward- looking statements. Mesoblast makes such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about the timing, progress and results of Mesoblast’s preclinical and clinical studies in CLBP; Mesoblast and its collaborators’ ability to advance product candidates into, enroll and successfully complete, clinical studies; the timing or likelihood of regulatory filings and approvals for CLBP; and the pricing and reimbursement of Mesoblast and its collaborators’ product candidates, if approved. You should read this press release together with Mesoblast’s risk factors, in Mesoblast’s most recently filed reports with the SEC or on Mesoblast’s website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. Mesoblast does not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. ▇▇▇▇▇▇ ▇▇▇▇▇▇▇, Head Global Communications, ▇▇▇▇▇ ▇▇▇▇▇▇▇, Global Head Corporate Grünenthal Communications, Mesoblast Tel.: +▇▇ ▇▇▇ ▇▇▇-▇▇▇▇ Tel.: +▇▇ ▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇ Melbourne, Australia ▇▇▇▇▇▇▇ ▇▇▇▇▇▇, Head Editorial Management & Schond Greenway, Investor Relations, Media Relations, Grünenthal Mesoblast Tel.: +▇▇ ▇▇▇ ▇▇▇-▇▇▇▇ Tel: +▇ ▇▇▇ ▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇▇, ▇▇▇ Yes Al. and our Business Partners should too. So. I understand that we...

Follow us on. “GGML’s support in this club has had a significant impact. The passion and effort of the players are the result of GGML’s investment. We sincerely appreciate the support,” she stated.

Follow us on. About Revive:

Follow us on q You plan on changing bank accounts and your direct deposit is going to change